Older drugs with limited trial evidence: Are they worth the expense? The case of repository corticotropin marketed as H.P. Acthar Gel

Ali Duarte-García; Eric L. Matteson; Nilay D. Shah

doi:10.7326/M18-3513

Older drugs with limited trial evidence: Are they worth the expense? The case of repository corticotropin marketed as H.P. Acthar Gel

Ali Duarte-García, Eric L. Matteson, Nilay D. Shah

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	791-793
Number of pages	3
Journal	Annals of internal medicine
Volume	170
Issue number	11
DOIs	https://doi.org/10.7326/M18-3513
State	Published - 2019

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.7326/M18-3513

Cite this

@article{f652e782bb6246ac90abd3be052b34cf,

title = "Older drugs with limited trial evidence: Are they worth the expense? The case of repository corticotropin marketed as H.P. Acthar Gel",

author = "Ali Duarte-Garc{\'i}a and Matteson, {Eric L.} and Shah, {Nilay D.}",

note = "Funding Information: From Mayo Clinic College of Medicine and Science, Rochester, Minnesota (A.D., E.L.M., N.D.S.) Financial Support: Dr. Duarte-Garc{\'i}a is supported by the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, which receives no industry funding.",

year = "2019",

doi = "10.7326/M18-3513",

language = "English (US)",

volume = "170",

pages = "791--793",

journal = "Annals of internal medicine",

issn = "0003-4819",

publisher = "American College of Physicians",

number = "11",

}

TY - JOUR

T1 - Older drugs with limited trial evidence

T2 - Are they worth the expense? The case of repository corticotropin marketed as H.P. Acthar Gel

AU - Duarte-García, Ali

AU - Matteson, Eric L.

AU - Shah, Nilay D.

N1 - Funding Information: From Mayo Clinic College of Medicine and Science, Rochester, Minnesota (A.D., E.L.M., N.D.S.) Financial Support: Dr. Duarte-García is supported by the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, which receives no industry funding.

PY - 2019

Y1 - 2019

UR - http://www.scopus.com/inward/record.url?scp=85067125429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067125429&partnerID=8YFLogxK

U2 - 10.7326/M18-3513

DO - 10.7326/M18-3513

M3 - Comment/debate

C2 - 31060052

AN - SCOPUS:85067125429

SN - 0003-4819

VL - 170

SP - 791

EP - 793

JO - Annals of internal medicine

JF - Annals of internal medicine

IS - 11

ER -

Older drugs with limited trial evidence: Are they worth the expense? The case of repository corticotropin marketed as H.P. Acthar Gel

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this